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pitalisation data from 2,074 patients with PD who were recruited into the PD 
MED trial from Nov 2000 to Dec 2009 and followed up for ten years. PD MED is a 
large-scale, “real-life” randomised controlled trial comparing the effectiveness and 
cost-effectiveness of PD medications. Patients’ demographic characteristics, dis-
ease severity, reasons and duration of hospitalisation were analysed. Reasons for 
hospitalisations were coded based on the International Classification of Disease 
(ICD-10). Results: Of 2,074 patients, at randomisation, median age was 72 years 
(IQR 66-77), mean duration with diagnosed PD was 2.8 years (median 2, IQR 1-3) and 
median Hoehn &Yahr score was 2 (IQR 1.5-2.5). Until Oct 2011, 29% (597/2074) of 
patients had a total of 941 hospitalisation records. Mean length of stay was 21days 
(median 9, IQR 3-24). Hospitalisation reasons were classified into 11 categories of 
PD related conditions and 15 PD unrelated categories. 64.1% of the hospitalisation 
records can be associated with PD. Main reasons for hospitalisation were: infec-
tions including pneumonia and urinary tract infection (18.4%), falls and fractures 
and other injuries (15.3%), cardiovascular and circulatory disorders (8.7%), central 
nervous system and disorders of sense organs (8.2%), gastrointestinal disorders 
(8.0%), and mental health disorders (6.9%). ConClusions: PD related conditions 
have a significant and broad ranging specialty impact on hospitalisation rates 
and associated health care costs are substantial. This paper provides economic 
justification for investing in interventions that manage infection and prevent 
falls in people with PD.
Neurological DisorDers – Patient-reported outcomes & Patient Preference 
studies
PND5
alzheimer’s Disease caregiver BurDeN iN JaPaN aND the 5 e.u
Gupta S.1, Fukuda T.2, Okumura Y.3, Stankus A.P.1
1Kantar Health, Princeton, NJ, USA, 2National Institute of Public Health, Saitama, Japan, 3Institute 
for Health Economics and Policy, Tokyo, Japan
objeCtives: Alzheimer’s disease (AD) is a chronic and progressive disease that 
is a significant burden on caregivers. Research indicates AD caregiver burden 
on health status; but there is limited research on caregiver burden in Japan. The 
objectives of this study were to examine Japan AD caregiver burden vs. Japan non-
caregivers and 5E.U. AD caregivers. Methods: Data were obtained from the 2012 
Japan (N= 30,000) National Health and Wellness Survey (NHWS) and 2013 5E.U. (UK, 
Germany, France, Italy, Spain; N= 62,000) NHWS, administered online to a representa-
tive adult sample (18+ years). Respondents reported on health status (SF-36v2), 
activity impairment, health care utilization in the past six months and caregiver 
responsibilities. Multivariable regressions, adjusting for demographics and health 
history variables to explore differences between Japan AD caregivers (n= 714) vs. 
Japan non-caregivers (n= 27,702) and 5E.U. AD caregivers (n= 1,239). Results: Japan 
AD caregivers were older and reported more depression symptoms than Japan non-
caregivers (p< 0.05). Japan AD vs. 5E.U. AD caregivers were older and more educated 
(p< 0.05). After adjustments, Japan AD caregivers had lower health status (p< 0.001), 
higher health care utilization, and greater activity impairment (p< 0.001) than Japan 
non-caregivers. Japan AD vs. 5E.U. AD caregivers had better mental (45.7 vs. 43.8, 
p< 0.001) and physical (51.0 vs. 50.0, p= 0.021) health status, marginally less activity 
impairment (24.5% vs. 27.1%, p= 0.070), but more health care provider visits (7.6 vs. 
5.4, p< 0.001) and hospitalizations (p< 0.001). Japan AD caregivers vs. 5E.U. caregivers 
were less likely to make treatment decisions and manage finances for AD relative 
(p< 0.001), were marginally less involved in helping with daily activities (transporta-
tion, meals, shopping, p= 0.054), but no difference was found on bathing/grooming 
involvement. ConClusions: Japan AD caregivers report more burden including 
more depression symptoms than Japan non-caregivers. Japan AD caregivers report 
greater health care utilization than 5E.U. AD caregivers, but report better health 
status, and less involvement in treatment and finance decisions.
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objeCtives: Multiple Sclerosis (MS) is a chronic disease which results in increasing 
disability over time. The Australian Multiple Sclerosis Longitudinal Study (AMSLS) 
is an ongoing study that collects information on around 3,100 volunteers with MS 
from all States and Territories in Australia. The WHO quality of life assessment 
instrument (WHOQOL-100) was collected as well as the following Patient Reported 
Outcome (PRO) measures; MS Self-Efficacy Scale, Perceived Stress Scale, Geriatric 
Depression Scale – short version (GDP-5), Social Support Scale, Therapeutic Self-Care 
Scale, and the Depression Anxiety and Stress Scale (DASS). In this analysis, we quan-
tified the difference in utility, stress, depression and social support needs between 
disease severities in subjects with MS. Methods: Data from the WHOQOL-100 
were collected in 2008. The utility score was calculated by mapping five questions 
from the WHOQOL-100 to the EQ-5D descriptive system as described by Al-Ruzzeh 
et al (2008). The UK TTO value set (utility weights) were applied to each of the lev-
els in each dimension. Disease severity was based on the self reported Disease 
Steps Scale. Results: A total sample of 2139 subjects provided evaluable data; 
a response rate of approximately 70%. Overall average QOL as measured by the 
WHOQOL-100 was 13.7 (95%CI: 13.5 to 13.8) out of a maximum value of 20, ranging 
from 11.8 (95%CI: 11.4 to 12.2) in severe disease to 15.2 (95%CI: 15.0 to 15.4) when 
mild. The utility score for all people with MS was 0.65 (95%CI: 0.64 to 0.67). The 
utility decreased with increasing disease severity with values of 0.80 (95%CI: 0.78 
to 0.81), 0.60 (95%CI: 0.58 to 0.61) and 0.42 (95%CI: 0.39 to 0.46) for mild, moderate 
and severe disease, respectively. The other instruments on the whole followed this 
trend. ConClusions: Higher disease severity in subjects with MS is associated 
with lower utility and QOL and worse outcomes in general.
outcomes, and study designs). Results: A review of the clinical efficacy of ivacaftor, 
its comparative clinical efficacy compared with dornase alfa, and a review of the 
cost-effectiveness of ivacaftor will help to inform decisions about the treatment of 
patients with CF. Four studies were presented as evidence of the benefit of ivacaftor 
in CF. Two pivotal trials STRIVE and ENVISION, one open label extension study, 
PERSIST, for patients in STRIVE and ENVISION and a final study in different patient 
group, DISCOVER, in patients who are homozygous for the F508del mutation. The 
percent predicted forced expiratory volume in 1 second (FEV1) was the primary 
outcome measure for the two phase III clinical trials. The review group noted the 
absence of long term efficacy data particularly in relation to the benefit of ivacaftor 
in maintaining percent predicted FEV1 and reducing pulmonary exacerbations and 
the resultant impact on survival rates. The analysis for this extrapolation is based on 
a number of prediction models that have been published. The disease progression 
model predicts that the median survival for a patient treated with ivacaftor will 
be 29.2 years longer as a consequence of taking the drug. ConClusions: Whilst 
ivacaftor may represent an innovation for the treatment of patients with cystic 
fibrosis there are significant uncertainties, including the absence of long term health 
outcome data.
Neurological DisorDers – cost studies
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objeCtives: To determine the trend of drug utilization for Alzheimer’s disease 
during 2009 and 2013. Methods: Prescription data of outpatients with Alzheimer’s 
disease in 2009 – 2013 was extracted from the medical care database of the hospital. 
Quantities and costs of the prescribed drugs were examined using defined daily dose 
(DDD) for comparisons. Results: Number of patients was rather the same number 
every year ranging from 1,507 to 1,631 patients. For donepezil and memantine, 
number of DDD per year was increased every year ranging from 7.3–10.0 % to 1.6-
14.7% compared to the previous year, respectively. The increasing trends were not 
found in prescribing of rivastigmine, except for the dramatically increase (34.0%) 
in 2013. Galantamine was prescribed less in 2010 and 2013 accounted for -9.2 and 
-18.2%, respectively. Cost of drug use in Alzheimer’s disease was $3,211,269 in 2009 
and $3,228,454 in 2013 with an increasingly trend. ConClusions: The overall drug 
use in Alzheimer’s disease seems to be a heavy burden of the hospital every year. 
The rational drug use should be confirmed to make sure to guarantee appropriate 
use of drug without overusage.
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objeCtives: The purpose of this study was to review cost-effectiveness models in 
multiple sclerosis (MS) to identify accepted methods, key challenges, and best prac-
tices.  Methods: We searched MEDLINE, Embase, the Health Economics Evaluation 
Database (HEED), the Cochrane library, and recent HTA agencies’ (NICE and SMC) deci-
sions  for studies published prior to March 7, 2014. Following duplicate removal, 100 
studies were identified. Studies were excluded if they did not estimate cost-effective-
ness in MS, were duplicates, or weren’t published in English, resulting in a total of 26 
studies sourced. A data extraction form was developed to capture information about 
model characteristics, patient natural history progression, utility estimates, and the 
author’s comments on the modelling methods. Results: All studies were published 
after 2000, with most focused on first-line USA and EU patient populations. The major-
ity of models utilised a cohort Markov model approach, with health states defined by 
patient expanded disability status scale (EDSS) scores. Health states included either 
individual or aggregate EDSS scores (0-9.5) for relapsing-remitting MS (RRMS) and sec-
ondary progressive MS (SPMS), as well as a death state. Transition probabilities were 
sourced from trial data for low score EDSS states, while transitions for higher score 
EDSS states were sourced from a longitudinal study of Canadian MS patients, due 
to insufficient clinical trial data for patients with advanced disease. Key challenges 
identified in recent HTA decisions include modelling EDSS score improvement early 
in disease natural history, patients’ initial distributions across EDSS states, extended 
benefits of therapy, and patient treatment adherence. ConClusions: Established 
modelling best practice in MS utilises a cohort Markov model approach with health 
states simulating patient populations via EDSS scores in RRMS and SPMS. Future 
studies and HTA submissions should focus on more accurately reflecting patient 
natural history in the early stages of disease.
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objeCtives: Reasons for hospitalisations in people with Parkinson’s Disease 
(PD) are broad ranging and costly, however detailed analysis of hospitalisations 
in a large, representative group of PD patients is lacking. This study aimed to 
explore the reasons for, resource use and associated cost of hospital treatment 
in participants in the PD MED trial. Methods: We retrospectively reviewed hos-
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objeCtives: The purpose of our study is to assess the frequency related to Diseases 
of the nervous system within out-patient care and determine the total health care 
expenses of them in Hungary in 2009. METHODS: CONCLUSIONS:  Methods: Data 
were derived from the nationwidewide database of Hungarian National Health 
Insurance Fund Administration (NHIFA), based on official reports of outpatient care 
institutes. The 151 different types of treatment codes are listed in the chapter of 
the Guidelines of NHIFA for `Physiotherapists, massage-therapists, conductors and 
other physiotherapy practices`. The diseases of the nervous system are listed in 
the International Classification of Diseases (ICD) with code of G00-G99.  Results: 
Diseases of the nervous system account for 1.331.675 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approximately 
4,12% prevalence. The following top-10 medical procedure were responsible for 48.48% 
(645562) of total activities: individual training (7.79 %), passive motion therapy on mul-
tiple limbs (6.24%),selective nerve stimulation therapy (5.89%), muscle strengthening 
exercise (5.82%), training for circulation improvement (4.6%), parts of the body per 
individual physiotherapy (4.19%), ergotherapy (3.78%), exercise to prevention of car-
diovascular complications (3.68%), Hand massage (3.53%), electrotherapy - facial nerve 
(2.96%). The total financial cost of all of the physiotherapeutic treatments provided in 
diseases of the nervous system was 388 million Hungarian Forint (1.25 million Euro) 
health insurance subsidy in 2009. ConClusions: The 20 most frequent treatments 
accounts for 71.72 % (955073) of total services. The passive procedures are more com-
mon than the active in the 20 most commonly used activities list. Our results could 
be extremely useful for economic evaluation of the health care system and in the 
financial planning of the treatments of the studied diseases of the nervous system.
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iN mice: eviDeNce for iNvolvemeNt of oxiDative stress aND 
iNflammatory Pathway
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objeCtives: A wide body of literature suggest in vivo neuroprotective, antioxidant, 
anti-inflammatory and anti-ageing properties of Sesamol. This study was aimed 
to elucidate the protective effect of sesamol in experimental model of chronic 
fatigue syndrome (CFS). Methods: Firstly, Sesamol was tested for its antidepres-
sant potential in mouse models using forced swim test (FST) and tail suspension 
test (TST). Later, Sesamol was examined in mouse model of chronic stress fatigue 
induced by chronic forced swimming for 15 days. Brain biochemical [superoxide 
dismutase (SOD), glutathione-S-transferase (GST), glutathione (GSH), lipid peroxi-
dation and nitrite levels) and plasma cytokines [tumour necrosis factor α (TNF-α ) 
and interleukin 6 (IL-6)] levels were assessed to correlate the possible mechanism 
of action associated with fatigue symptoms. Further, adrenal ascorbic acid meas-
urement was done to correlate corticosterone levels. Results: Mice administered 
with sesamol showed significant decrease in immobility time in acute FST and 
TST. Sesamol significantly attenuated progression of CFS in experimental model as 
compared to control. Sesamol also corrected the other cognitive deficits (locomo-
tor activity, motor activity, memory retention, hyperalgesia) associated with CFS. 
Furthermore, it rectified the diminished levels of antioxidant enzymes such as SOD, 
GST and GSH in brain and altered levels of proinflammatory cytokines (TNF-α and 
IL-6). ConClusions: This finding suggests that anti-fatigue activity of sesamol 
against chronic induced fatigue in mice. The present outcome offers a therapeutic 
application of sesamol against CFS and also offers the scope for its development 
against neuropsychiatric disorders.
uriNary/kiDNey DisorDers – clinical outcomes studies
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systematic review of aDverse eveNts
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objeCtives: Benign prostatic hyperplasia (BPH) is an age related disorder, however 
its symptoms begin to appear in some men as early as age 40 years. As per estimates 
every second person has BPH by the age of 60 and 90% of individuals develop BPH 
by 85 years. Tadalafil is a selective PDE5 enzyme inhibitor approved to treat men 
with BPH. The aim is to systematically review the medical literature for randomized 
control trial and identify the adverse events (AE) associated with tadalafil use in 
BPH. Methods: All published randomized controlled trials (RCTs) comparing tada-
lafil with a placebo or active interventions for the treatment of BPH with or without 
any co-morbidity (such as but not limited to erectile dysfunction) were sought from 
PubMed, EMBASE, Cochrane Library, and Google Scholar. Abstracts, titles and then 
the full-text manuscripts of all selected articles will be retrieved and assessed by 
two independent reviewers against the eligibility criteria. Disagreements over study 
inclusion will be resolved through discussion. A pre-designed data extraction form 
will be used by two reviewers for the extraction of AE and other study findings. 
Cochrane risk of bias assessment checklist will be used for the risk of bias assess-
ment. An Excel spreadsheet will be used to extract data from the selected articles. 
Descriptive and quantitative data synthesis will be done for AE reported in all the 
studies. Meta-analysis will be performed using RevMan (v5.0). Results: Though 
there are several studies assessing tadalafil use in erectile dysfunction, a system-
atic review/meta-analysis of the evidence reporting its AE profile when used for 
Neurological DisorDers – health care use & Policy studies
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objeCtives: In Japan, the Specified Disease Treatment Research Programme pro-
vides copayment reduction or exemption for patients with 56 designated rare 
and intractable diseases/syndromes according to disease severity and patients’ 
income levels. The objective of this study is to examine the impact of the Specified 
Disease Treatment Research Programme on generic drug utilisation under the fee-
for-service payment system. Methods: We extracted and analysed claims data 
with indication for Parkinson’s disease, which is subject to the Specified Disease 
Treatment Research Programme, from the Social Health Insurance claims data 
processed from February to April 2011. Extracted data were analysed in terms of 
patients’ age and income levels, types of public subsidy, prescribed places (clinic/
hospital or pharmacy) and pharmacologic classes. Results: During the three 
months, cumulative total number of 72,145 patients in Social Health Insurance 
programme were prescribed drugs for Parkinson’s disease, of which 10,013 were 
entitled to the Specified Disease Treatment Research Programme. Overall average 
generic utilisation rate is 15.46% on a volume basis. Average generic utilisation rate 
for those entitled to the Specified Disease Treatment Research Programme is 4.04%, 
whilst for patients eligible for medical assistance programme is 21.75%. Generic 
utilisation is fewer in the elderly than in the younger generation. ConClusions: 
Our study finds low generic utilization rate for patients with Parkinson’s disease 
entitled to the Specified Disease Treatment Research Programme. This might be 
suggesting that without mandatory clinical guidelines nor guidance for generic 
substitution, the Specified Disease Treatment Research Programme has been pro-
moted branded prescribing under the fee-for-service system. Additional studies 
with other designated rare and intractable diseases/syndromes are expected to 
generalise the study result.
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acetyl-l-carNitiNe for the treatmeNt of PeriPheral NeuroPathic 
PaiN: a systematic review aND meta-aNalysis
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objeCtives: Acetyl-L-carnitine (ALC), as a constructive component in fatty acid 
metabolism, is considered a potential agent for peripheral neuropathic pain (PNP). 
We aimed to access the efficacy and safety of ALC for the treatment of patients 
with PNP. Methods: We searched PubMed up to March 2014 for randomized 
controlled trials (RCTs) comparing ALC with placebo or other active medications 
in diabetic and non-diabetic PNP patients. Two reviewers independently screened 
for eligible studies, assessed risk of bias, and extracted data. Mean difference (MD) 
and 95% confidence interval (CI) were used for pooling continuous data. Results: 
Four RCTs compared ALC with placebo and reported in 3 articles (n = 523) were 
included. Compared with placebo, ALC significantly reduced Visual Analogue Scale 
(VAS) of PNP patients (MD, 1.28; 95%CI, 0.93-1.64, P < 0.00001). In the subgroup 
analysis, the efficacy of ALC on VAS was similar in different administration route 
(intramuscular-oral sequential subgroup: MD, 1.19; 95% CI, 0.34-2.04, P = 0.006; oral 
only subgroup: pooled MD, 1.15; 95% CI, 0.33-1.96, P = 0.006), and ALC appeared 
more effective in diabetic PNP patients than non-diabetic PNP patients (diabetic 
subgroup: MD, 1.47; 95% CI, 1.06-1.87, P < 0.00001; non-diabetic subgroup: MD, 0.71; 
95% CI, -0.01-1.43, P = 0.05). No severe adverse events related to ALC were reported. 
The common adverse events were pain, headache, paraesthesia, hyperesthesia, 
retching, biliary colic and gastrointestinal disorders. The rates of total adverse 
events were similar in ALC and control group. ConClusions: ALC could reduce 
VAS in PNP patients with acceptable safety. However, further trials with larger 
population and longer follow-up are required to confirm these findings.
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objeCtives: The aim of our study is to assess the utilization of out-patient care 
physiotherapy services related to cerebral palsy and other paralytic syndromes 
according to age and gender. Methods: The data come from the financial data 
base of the National Health Insurance Fund Administration involving the year 
of 2009. The activity list was provided by the rulebook on the application of the 
activity code list in out-patient care. The Cerebral Palsy and other paralytic 
syndromes are listed in the International Classification of Diseases (ICD) with 
code of G80-G83. The number of cases in physiotherapy activities were deter-
mined per 10000 persons by age and gender in outpatient care, 2009. Results: 
Diseases of the nervous system account for 1331675 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approxi-
mately 4.12% prevalence. The prevalence of the Cerebral Palsy and other para-
lytic syndromes were 31.56% in the group of of diseases of the nervous system. 
The average number of cases of physiotherapy activities per 10000 persons 
accounted for 433 cases in 2009. The average number of cases per 10000 persons 
for males and females were 508 cases for males and 364 cases for females. 
The high number of physiotherapy treatment is provided for both gender in 
the youngest age group and 60-74 age groups in male and 70-84 age groups 
in female. ConClusions: The cerebral palsy and other paralytic syndromes 
at the diseases of the nervous system show high prevalence, indicating the 
importance of prevention.
